首页> 外文OA文献 >Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia

【2h】

Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia

机译：皮下Alemtuzumab（抗CD52单克隆抗体，坎塔及-1H）治疗作为B细胞慢性淋巴细胞白血病的一线治疗后细胞免疫重建

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
J Lundin; A Porwit-MacDonald; E D Rossmann; C Karlsson; P Edman; M R Rezvany; E Kimby; A Österborg; H Mellstedt;
展开▼
作者单位

展开▼
年度 2004
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia [J] . J Lundin, A Porwit-MacDonald, E D Rossmann, Leukemia . 2004,第3期

机译：皮下注射alemtuzumab（抗CD52单克隆抗体，CAMPATH-1H）治疗后的细胞免疫重建是B细胞慢性淋巴细胞白血病的一线治疗
2. P27. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL) – a single region experience on consecutive patients [J] . S Eketorp Sylvan, J Lundin, M Ipek, Journal for ImmunoTherapy of Cancer . 2014,第S2期

机译：P27。 Alemtuzumab（抗CD52单克隆抗体）作为复发/难治性慢性淋巴细胞白血病（CLL）患者的单药治疗–连续患者的单区域经验
3. In vitro and in vivo evaluation of direct rhenium-188-labeled anti-CD52 monoclonal antibody alemtuzumab for radioimmunotherapy of B-cell chronic lymphocytic leukemia. [J] . De-Decker M, Bacher K, Thierens H, Nuclear Medicine and Biology . 2008,第5期

机译：直接rh 188标记的抗CD52单克隆抗体alemtuzumab的体外和体内评估，用于B细胞慢性淋巴细胞性白血病的放射免疫治疗。
4. Efficiency and Toxmcity of the Fludarabine and Cyclo- Phosphamide Combined Therapy in Relapsed/ Resistant Patients with B-cell Chronic Lymphocytic Leukaemia (CLL)-Polish Multicenter Study [C] . M. Kowal, A. Dmoszynska, D. Jawniak, European Haematology Association . 2002

机译：B-Cell慢性淋巴细胞白血病（CLL） - 渗透多中心研究的复发/抗性患者复发/抗性患者的氟氮胺碱和环磷酰胺联合治疗的效率和毒性
5. Omega-3 fatty acids as therapeutic options for the treatment of B-cell chronic lymphocytic leukemia. [D] . Fahrmann, Johannes Francois. 2013

机译：Omega-3脂肪酸可作为治疗B细胞慢性淋巴细胞性白血病的治疗选择。
6. P27. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL) – a single region experience on consecutive patients [O] . S Eketorp Sylvan, J Lundin, M Ipek, 2014

机译：P27。 Alemtuzumab（抗CD52单克隆抗体）作为复发/难治性慢性淋巴细胞白血病（CLL）患者的单药治疗–连续患者的单区域经验
7. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). [O] . Lundin J, Kimby E, Björkholm M, 2002

机译：皮下抗CD52单克隆抗体alemtuzumab（Campath-1H）作为B细胞慢性淋巴细胞性白血病（B-CLL）患者的一线治疗的II期试验。

Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia

著录项

引文网络

相似文献

相关主题

期刊订阅